Prostate Cancer Clinical Trial

ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

Summary

A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.

Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male 18 years of age or older
Has tumor tissue available for diagnostics
Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. Patients must continue on a LHRH analogue (unless the patient had an orchiectomy) throughout the course of the study
ECOG score of 0 or 1

Exclusion Criteria:

Any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior EGFr targeting agent)
Prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed)
Known to be HIV positive
Myocardial infarction within one year prior to entering the study

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

50

Study ID:

NCT00061126

Recruitment Status:

Completed

Sponsor:

Abgenix

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States
UCLA School of Medicine
Los Angeles California, 90095, United States
Stanford Medical Center
Stanford California, 94303, United States
Advanced Research Institute
New Port Richey Florida, 34652, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
University of Pittsburgh Cancer Institute, Hillman Cancer Center
Pittsburgh Pennsylvania, 15232, United States
Urology San Antonio Research
San Antonio Texas, 78229, United States
University of Washington
Seattle Washington, 98109, United States
Madigan Army Medical Center
Tacoma Washington, 98431, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

50

Study ID:

NCT00061126

Recruitment Status:

Completed

Sponsor:


Abgenix

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider